Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model

International Journal of Immunopathology and Pharmacology
Antonio Di StefanoCinzia Nasuti

Abstract

Both oxidative stress and inflammation are elevated in brains of Alzheimer's disease patients, but their pathogenic significance still remains unclear. Current evidence support the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) and antioxidant therapy might protect against the development of Alzheimer's disease, and ibuprofen has the strongest epidemiological support. In the present work our attention was focused on (R)-alpha-lipoic acid considered as a potential neuroprotective agent in Alzheimer's disease therapy. In particular, we investigated a new co-drug (1) obtained by joining (R)-alpha-lipoic acid and ibuprofen via a diamide bond, for evaluating its potential to antagonize the deleterious structural and cognitive effects of beta-amyloid (1-40) in an infused Alzheimer's disease rat model. Our results indicated that infusion of beta-amyloid (1-40) impairs memory performance through a progressive cognitive deterioration; however, ibuprofen and co-drug 1 seemed to protect against behavioural detriment induced by simultaneous administration of beta-amyloid (1-40) protein. The obtained data were supported by the histochemical findings of the present study: beta-amyloid protein was less expressed in 1-treated t...Continue Reading

References

Aug 1, 1996·Trends in Neurosciences·G W Kreutzberg
Jan 1, 1997·Free Radical Biology & Medicine·L PackerK Wessel
Oct 7, 1998·Progress in Neurobiology·M A Cuadros, J Navascués
Dec 16, 1998·Journal of Neural Transmission. Supplementum·W RetzP Riederer
Aug 31, 2000·Annual Review of Biochemistry·W L SmithR M Garavito
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Martha Clare MorrisPaul A Scherr
Oct 26, 2002·Molecular Psychiatry·K L Davis
Jul 31, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Monisha Sharma, Y K Gupta
Jan 21, 2004·Archives of Neurology·Peter P ZandiUNKNOWN Cache County Study Group
Jun 16, 2004·International Journal of Pharmaceutics·Alf LamprechtJean-Pierre Benoit
Nov 22, 2005·Pharmacology, Biochemistry, and Behavior·Marcos Brandão ContóMarco Antonio Campana Benedito
Sep 23, 2006·Pharmacology & Therapeutics·Lina HolmquistGerald Münch
Nov 16, 2006·Current Pharmaceutical Design·Stefanie LeuchtenbergerSascha Weggen
Jul 29, 2008·Advanced Drug Delivery Reviews·Annette MaczurekGerald Münch
Dec 17, 2008·Current Pharmaceutical Design·Mie HirohataMasahito Yamada
Feb 27, 2010·Archiv der Pharmazie·Piera SozioAntonio Di Stefano

❮ Previous
Next ❯

Citations

Dec 4, 2010·The International Journal of Neuroscience·Dayane Pessoa De AraújoSilvania Maria Mendes Vasconcelos
May 10, 2016·Expert Opinion on Drug Delivery·Ibrahim A AljuffaliJia-You Fang
Jun 20, 2020·Medicinal Research Reviews·Claudia AlbertiniMaria L Bolognesi
May 11, 2012·Journal of Clinical Biochemistry and Nutrition·Vigneshwaran PitchaimaniKenichi Watanabe
May 3, 2013·Alzheimer's Research & Therapy·Laurent Lecanu, Vassilios Papadopoulos
Sep 24, 2011·Molecular Neurodegeneration·Andreas M GrabruckerTobias M Boeckers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.